F
Forte Biosciences, Inc. (FBRX)
NCM – Real vaqt narxi. Valyuta: USD
25.50
-1.51 (-5.59%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
25.50
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
25.50
-1.51 (-5.59%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
25.50
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:10 PM EDT
Forte Biosciences, Inc. Qo'shma Shtatlarda klinik bosqichdagi biofarmatsevtika kompaniyasi sifatida faoliyat yuritadi. Kompaniyaning asosiy mahsulot nomzodi FB-102 bo'lib, u transplantat-qarshi-xost kasalligi, vitiligo va alopesiya areata kabi turli autoimmün va autoimmün bilan bog'liq ko'rsatmalarga, shuningdek, çölyak kasalligi va nostegmental vitiligo uchun mo'ljallangan CD122 ga qarshi patentlangan monoklonal antiteladir. Forte Biosciences, Inc. shtab-kvartirasi Dallas, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director |
| Dr. Paul A. Wagner Ph.D. | CEO, President & Chairman |
| Mr. Antony A. Riley CPA | Chief Financial Officer |
| Mr. Christopher Roenfeldt | Chief Operating Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2025-11-14 | 10-Q | fbrx-20250930.htm |
| 2025-09-30 | S-8 | d83263ds8.htm |
| 2025-08-14 | 8-K | d939022d8k.htm |
| 2025-06-25 | 8-K | d944948d8k.htm |
| 2025-06-23 | 8-K | d874957d8k.htm |
| 2025-05-30 | 8-K | d908206d8k.htm |
| 2025-05-15 | 10-Q | fbrx-20250331.htm |
| 2025-04-30 | DEF 14A | d912010ddef14a.htm |
| 2025-04-18 | 8-K | d206139d8k.htm |
| 2025-04-04 | 8-K | d876988d8k.htm |